세계의 헌터증후군 치료 시장 예측 : 치료 유형별, 합병증 유형별, 투여 경로별, 중증도별, 최종 사용자별, 지역별 분석(-2030년)

According to Stratistics MRC, the Global Hunter Syndrome Treatment Market is accounted for $1.3 billion in 2024 and is expected to reach $1.9 billion by 2030 growing at a CAGR of 7.3% during the forecast period. Hunter Syndrome, a rare genetic disorder caused by a deficiency of the enzyme iduronate-2-sulfatase, leads to progressive health issues. Treatment primarily focuses on managing symptoms and improving quality of life. Enzyme replacement therapy (ERT) is the most common approach, providing patients with the missing enzyme to reduce substrate accumulation. Additional treatments may include physical therapy to maintain mobility, respiratory care to address breathing difficulties, and surgical interventions for orthopedic issues or organ function support.

According to the Genetic and Rare Diseases Information Center (GARD), there can be an estimated 7,000 rare diseases and the total number of individuals in the U.S. from these rare diseases can be 25-30 million.

Market Dynamics:

Driver:

Growing awareness of hunter syndrome

Growing awareness of Hunter Syndrome is reshaping the treatment market by promoting earlier diagnoses and a deeper understanding of the condition. Increased education among healthcare professionals and advocacy groups has spurred demand for innovative therapies, such as enzyme replacement therapy (ERT). This awareness fosters collaboration among stakeholders, enhancing patient support and outcomes, ultimately expanding treatment options and improving the overall landscape for those affected by the disorder.

Restraint:

Lack of skilled professionals

The lack of skilled professionals in the market poses significant challenges, leading to delayed diagnoses and suboptimal care for patients. Insufficient expertise can hinder effective implementation of innovative therapies, such as enzyme replacement and gene therapies. This shortage limits access to specialized treatment, reducing patient support and overall quality of care. Consequently, it exacerbates health disparities and diminishes the potential for improved outcomes in individuals affected by the disorder.

Opportunity:

Increased healthcare expenditure

Increased healthcare expenditure in the market reflects the rising demand for advanced therapies and comprehensive care. As awareness grows, investments in enzyme replacement therapy (ERT) and gene therapies expand, driving up costs associated with research, development, and patient management. This surge in spending aims to improve treatment accessibility and outcomes but may strain healthcare budgets. Ultimately, it highlights the need for sustainable funding and innovative approaches to support affected individuals effectively.

Threat:

Limited awareness in emerging markets

Limited awareness of Hunter Syndrome in emerging markets significantly hinders the treatment landscape, resulting in delayed diagnoses and inadequate access to care. Many healthcare providers may lack knowledge about the disorder, leading to misdiagnosis or underdiagnosis. This gap restricts the availability of innovative therapies ultimately impacting patient outcomes. Increased education and advocacy are essential to improve awareness and support for affected individuals in these regions.

Covid-19 Impact:

The COVID-19 pandemic adversely impacted the market by disrupting healthcare services and limiting access to essential therapies. Routine medical visits were postponed, delaying diagnoses and treatment initiation for many patients. Additionally, supply chain disruptions affected the availability of enzyme replacement therapies. The focus on pandemic response shifted resources away from rare diseases, highlighting the need for resilient healthcare systems that prioritize continuity of care for patients with rare conditions like Hunter Syndrome.

The musculoskeletal segment is projected to be the largest during the forecast period

The musculoskeletal segment is projected to account for the largest market share during the projection period. Patients may require interventions such as physical therapy, orthopedic surgeries, and pain management strategies to address these complications. The growing understanding of musculoskeletal manifestations drives demand for specialized treatments and multidisciplinary care approaches. Effective management is crucial to improving patients' quality of life and overall functional outcomes.

The diagnostic centers segment is expected to have the highest CAGR during the forecast period

The diagnostic centers segment is expected to have the highest CAGR during the extrapolated period. Advanced testing methods, including genetic testing and enzyme assays, are essential for confirming the disorder. Increased collaboration between diagnostic centers and healthcare providers enhances awareness and promotes timely intervention. As more centers specialize in rare genetic disorders, they contribute to improved patient outcomes and better access to targeted therapies, ultimately advancing care for those affected.

Region with largest share:

North America region is projected to account for the largest market share during the forecast period. Enzyme replacement therapy (ERT) has gained traction, supported by ongoing clinical research and patient advocacy efforts. Access to specialized care and diagnostic services is improving, although challenges remain in terms of cost and insurance coverage. The collaboration among healthcare providers, pharmaceutical companies, and advocacy groups is crucial for enhancing patient outcomes in the region.

Region with highest CAGR:

Asia Pacific is expected to register the highest growth rate over the forecast period due to increasing prevalence of genetic disorders. The market is characterized by diverse treatment modalities, including ERT, stem cell transplants, and surgical interventions, with ERT currently dominating due to its efficacy in managing symptoms like joint mobility and facial coarseness. Countries such as Japan and China are leading the charge, benefiting from early diagnosis and increased awareness of rare diseases.

Key players in the market

Some of the key players in Hunter Syndrome Treatment market include Takeda Pharmaceutical Company Limited, Medtronic, CANbridge Life Sciences Ltd., Novartis AG, Zimmer Biomet, Sangamo Therapeutics, F. Hoffmann-La Roche Ltd, Jasper Therapeutics, Inc., GSK Plc., Denali Therapeutics, Abbott, JCR Pharmaceuticals Co., Ltd. , Bayer AG, Johnson & Johnson Services, Inc. and Stryker Corporation.

Key Developments:

In September 2024, Denali Therapeutics announced plans to seek accelerated FDA approval for its investigational treatment, DNL310, to address Hunter syndrome (MPS II). Following productive discussions with the FDA, the company is set to submit a Biologics License Application (BLA) by early 2025.

In January 2024, Clinigen Group plc announced that it had received manufacturing and marketing approval for Hunterase (Disulfate-beta) ICV 15mg, under its strategic alliance with GC Pharma in Japan. This approval may help the company to acquire an enhanced customer base.

Treatment Types Covered:

• Enzyme Replacement Therapy (ERT)
• Hematopoietic Stem Cell Transplant (HSCT)
• Gene Therapy
• Other Treatment Types

Complication Types Covered:

• Cardiovascular
• Respiratory
• Musculoskeletal
• Neurological
• Ocular
• Hepatic
• Renal
• Hematological
• Other Complication Types

Route of Administration Covered:

• Intravenous (IV)
• Intracerebroventricular (ICV)

Severity Covered:

• Mild
• Moderate
• Severe

End Users Covered:

• Hospitals
• Diagnostic Centers
• Specialty Clinics
• Homecare Settings
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 End User Analysis
• 3.7 Emerging Markets
• 3.8 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Hunter Syndrome Treatment Market, By Treatment Type

• 5.1 Introduction
• 5.2 Enzyme Replacement Therapy (ERT)
• 5.3 Hematopoietic Stem Cell Transplant (HSCT)
• 5.4 Gene Therapy
• 5.5 Other Treatment Types

6 Global Hunter Syndrome Treatment Market, By Complication Type

• 6.1 Introduction
• 6.2 Cardiovascular
• 6.3 Respiratory
• 6.4 Musculoskeletal
• 6.5 Neurological
• 6.6 Ocular
• 6.7 Hepatic
• 6.8 Renal
• 6.9 Hematological
• 6.10 Other Complication Types

7 Global Hunter Syndrome Treatment Market, By Route of Administration

• 7.1 Introduction
• 7.2 Intravenous (IV)
• 7.3 Intracerebroventricular (ICV)

8 Global Hunter Syndrome Treatment Market, By Severity

• 8.1 Introduction
• 8.2 Mild
• 8.3 Moderate
• 8.4 Severe

9 Global Hunter Syndrome Treatment Market, By End User

• 9.1 Introduction
• 9.2 Hospitals
• 9.3 Diagnostic Centers
• 9.4 Specialty Clinics
• 9.5 Homecare Settings
• 9.6 Other End Users

10 Global Hunter Syndrome Treatment Market, By Geography

• 10.1 Introduction
• 10.2 North America
  • 10.2.1 US
  • 10.2.2 Canada
  • 10.2.3 Mexico
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 Italy
  • 10.3.4 France
  • 10.3.5 Spain
  • 10.3.6 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 Japan
  • 10.4.2 China
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 New Zealand
  • 10.4.6 South Korea
  • 10.4.7 Rest of Asia Pacific
• 10.5 South America
  • 10.5.1 Argentina
  • 10.5.2 Brazil
  • 10.5.3 Chile
  • 10.5.4 Rest of South America
• 10.6 Middle East & Africa
  • 10.6.1 Saudi Arabia
  • 10.6.2 UAE
  • 10.6.3 Qatar
  • 10.6.4 South Africa
  • 10.6.5 Rest of Middle East & Africa

11 Key Developments

• 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 11.2 Acquisitions & Mergers
• 11.3 New Product Launch
• 11.4 Expansions
• 11.5 Other Key Strategies

12 Company Profiling

• 12.1 Takeda Pharmaceutical Company Limited
• 12.2 Medtronic
• 12.3 CANbridge Life Sciences Ltd.
• 12.4 Novartis AG
• 12.5 Zimmer Biomet
• 12.6 Sangamo Therapeutics
• 12.7 F. Hoffmann-La Roche Ltd
• 12.8 Jasper Therapeutics, Inc.
• 12.9 GSK Plc.
• 12.10 Denali Therapeutics
• 12.11 Abbott
• 12.12 JCR Pharmaceuticals Co., Ltd.
• 12.13 Bayer AG
• 12.14 Johnson & Johnson Services, Inc.
• 12.15 Stryker Corporation